About Renova Therapeutics
Renova Therapeutics is a Healthcare company based in San Diego (United States) founded in 2009. Gene therapies for heart failure and diabetes are developed. Renova Therapeutics has raised $7.69 million across 5 funding rounds from investors including NIH and HHS. Renova Therapeutics offers products and services including RT-100 and RT-200. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of gene therapies for congestive heart failure and type 2 diabetes. The companys lead product, RT-100 for congestive heart failure (CHF) is a single-dose treatment designed to safely improve heart function. The second candidate for diabetes, RT-200, delivers a therapeutic gene urocortin 2 using a single intravenous injection. The company is also developing RT 400, a peptide therapy for acute decompensated heart failure.
- Headquarters San Diego, United States
- SectorsHealthcare
- Website renovatherapeutics.com
- Social LinkedIn X
- Total Equity Funding$7.69M (USD)
in 5 rounds
- Latest Funding Round$166.5K (USD), Series C
Jul 2024
- InvestorsNIH
& 1 more
Products & Services of Renova Therapeutics
Renova Therapeutics offers a comprehensive portfolio of products and services, including RT-100 and RT-200.
Delivers AC6 gene transfer to treat congestive heart failure in patients.
Provides Urocortin 2 gene transfer for type 2 diabetes management.
Funding Insights of Renova Therapeutics
Renova Therapeutics has successfully raised a total of $7.69M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $166.5 thousand completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.69M
- Total Rounds 5
- Last Round Series C — $166,500
- First Round $1.84M
(May 2014)
- Investors Count 2
All 5 funding rounds of Renova Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Renova Therapeutics
Renova Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Renova Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Renova Therapeutics
4 people are tracked at Renova Therapeutics (4 in leadership).
| Name | Role | Group |
|---|---|---|
Vijay Mahant | President and CEO | Leadership |
Peter Gengo | Vice President | Leadership |
William Davidson | Director | Leadership |
Pierre Lecocq | Director | Leadership |
Complete people profiles for Renova Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Renova Therapeutics
3 dated milestones of Renova Therapeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Renova Therapeutics is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Series C, of $166K.
Competitors of Renova Therapeutics
Renova Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Renova Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Renova Therapeutics
The website of Renova Therapeutics (renovatherapeutics.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 27.2% vs previous month
Websites whose visitors overlap most with Renova Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
siliciumlaboratories.com | siliciumlaboratories.com | 100% | #13,118,085 | – | |
telephonestuff.com | telephonestuff.com | 92% | #15,302,430 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Renova Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Renova Therapeutics
Complete news archive for Renova Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renova Therapeutics
Renova Therapeutics was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Renova Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Renova Therapeutics is a funded company, having raised a total of $7.69M across 5 funding rounds to date. The company's 1st funding round was a Grant of $1.84M, raised on May 2014.
Developer of gene therapies for congestive heart failure and type 2 diabetes. The companys lead product, RT-100 for congestive heart failure (CHF) is a single-dose treatment designed to safely improve heart function. The second candidate for diabetes, RT-200, delivers a therapeutic gene urocortin 2 using a single intravenous injection. The company is also developing RT 400, a peptide therapy for acute decompensated heart failure.
Renova Therapeutics's top competitors include BridgeBio, Forge Biologics and Insitro.
Renova Therapeutics offers RT-100 and RT-200.